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Objectives: The economical crisis and the requirements for structural changes 
in all aspects of public health brought a new era of reforms in the country as well 
as the health care system itself. The Pharmaceutical Legislation, both European 
and national, were implemented to protect public and state interests. Application 
of new legislation influenced provider of health care services in different areas. 
Therefore it is important to evaluate the impact and performance on costs and 
revenues of health care services provider. MethOds: Monitoring, calculation and 
assessment of costs and revenues with the help of financial analysis indicators 
for years 2003-2012, using financial statements was conducted, with respect to 
profitability, debt, liquidity, working capital and efficiency ratios. These ratios con-
stituted significant information of implementing new health care legislation and 
price policies. Results: In case of profitability, parameter gross profit ranged from 
x2003–2011= 16.1–22.8% (xaverage= 19.2%, Xmean= 19.8%, σ = 2.4), but in 2012 decreased on 
14.3%. Net profit ranged x2003–2011= 12.8–18.3% (xaverage= 14.6%, Xmean= 16.6%, σ = 4.9%), 
while in 2012 reached only 2.3%. Debt parameters varied from x2003–2012= 2.33-4.8 
(xaverage= 3.44, Xmean= 3.06, σ = 0.82), liquidity parameters current ratio x2003–2012= 1.1-
1.7 (Xaverage= 1.43, Xmean= 1.45, σ = 0.15) and quick ratio x2003–2012= 0.7-1.3 (xaver-
age= 1.16, xmean= 1.09, σ = 0.15), working capital ratio x2003–2012= 2,7-12,9, (Xaverage= 9.6, 
Xmean= 10.1, σ = 3.1) and efficiency ratios were measured either. cOnclusiOns: 
Implementation of new health care legislation and price policy that were intended 
to apply restrictive measures to increase system efficiency and cost savings had a 
significant impact on health care services providers by worsening profitability and 
liquidity parameters as key indicators of provider stability. Despite the improvement 
in debt ratio, working capital ratio and efficiency ratios, stability may be threatened 
and may affect the amount of health care services providers.
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Objectives: This study aims to assess the extent of the restriction on access to 
medicines in Bosnia and Herzegovina in relation to the country’s decentralised 
provision of health care, with three separate state entities and 10 cantons within 
the federation of Bosnia and Herzegovina all having a role in the provision of pub-
lic health care. MethOds: A comparison was made between the contents of the 
federal essential drug list and the drug lists of the various entities and cantons, in 
order to ascertain which medicines were available, at what price, and with what 
level of reimbursement. Results: The federal essential list contains the basic INNs 
which must be provided by each canton, but there were some important differences 
between the lists of the various entities and cantons. For example, the range of 
patented and originator medicines available in the Republic of Srpska was greater 
than in the cantons of the federation of Bosnia and Herzegovina in general. Also, 
within the federation, there was some variation in the price of medicines between 
cantons, and an even greater variation between the reimbursement levels paid for 
them. For example, in the Tuzla canton, a package of generic losartan produced by 
Krka was priced at 9.30 convertible marks and reimbursed at 20% by the canton’s 
health insurance fund, while the same package at the same price was reimbursed 
50% in the West Herzegovina canton. cOnclusiOns: The lack of centralised control 
over drug funding means that citizens face variability in access to medicines across 
the spectrum, depending on which entity or canton they live in. Recent regulatory 
changes aimed at bringing greater control into drug pricing have so far failed to 
have any notable impact.
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Objectives: To compare the Risk-Sharing Schemes (RSSs) proposed in reimburse-
ment applications received by Agency for Health Technology Assessment in Poland 
(AHTAPol) in 2012 and 2013. MethOds: Comparative analysis of RSSs proposed in 
reimbursement applications received by AHTAPol in 2012 and 2013 was conducted. 
RSSs were quantitatively and qualitatively analyzed and classified on the basis of 
both Carlson’s approach and the Polish Act on the reimbursement of medicinal 
products. Results: In years 2012 and 2013, 56 reimbursement applications with 26 
proposed RSSs and 80 reimbursement applications with 52 RSSs proposed received by 
AHTAPol, respectively. They were classified into 5 categories according to the Act on 
the reimbursement. The most common category in 2012 was making the official sales 
price dependent on the applicant providing supplies at a reduced price (34.62%). On 
the other hand, in 2013 the most common category was making the official sales price 
dependent on a pay-back of a part of the reimbursement obtained to the entity which 
is obliged to finance benefits with public funds (48.08%). Further categories were also 
analyzed. Among all RSSs proposed in each year, only 17 of 52 in 2013 and 9 of 26 
(1 proposition included more than one category) in 2012 could be classified according 
to the Carlson’s approach. As a Results, most common categories were Price Volume 
Agreements (4 in 2012 and 10 in 2013) and Manufacturer funded treatment initiation 
(4 in 2012 and 6 in 2013). Both in 2012 and 2013, there were only one RSSs dependent 
on the health effects achieved. cOnclusiOns: Most of the propositions both in 2012 
and 2013 are not considered to be RSS according to the Carlson’s approach. In 2013 
compared to 2012 there were less price reduction schemes and more pay-back based 
schemes. There is a strong need for further research.
BCMA system was compared. We also collected the numbers of phone calls for 
tracking stat drugs from Oct 2nd to Nov 15th in 2012. Results: After the implemen-
tation of the BCMA system, the medication error rate was significantly reduced 
from 0.18% to 0.12% (p < 0.05). Pharmacists agreed that the BCMA system pro-
vides assistance in tracking prescriptions (90%), identifying medications (60%), 
and reducing medication errors (53%). However, pharmacists also think that the 
system has increased their routine workload (57%). Nurses agreed that the BCMA 
system can improve patient identification (73%), administration of right medica-
tion (57%), medication administration time (47%), and access to correct prescrip-
tion/medication information (42%). Both pharmacists and nurses were dissatisfied 
with the stability of the system (53%, 69%) and poor barcode sensitivity (47%, 
64%). From Oct 2nd to Nov 15th in 2012, we received 469 phone calls. The average 
of tracing call for drugs is 1.67 times every hour. cOnclusiOns: BCMA system 
significantly decreases medication error rate in the hospital. It is recognized to be 
able to improve medication safety by both pharmacists and nurses. Improving the 
quality of associated computer equipment is the next important step.
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Objectives: Our study evaluates the preferred methods which the pharmaco-
economic evaluations submitted for reimbursement purposes in Bulgaria are 
using. MethOds: This is retrospective, descriptive study. We have examined 
all applications submitted to National Council on Pricing and Reimbursement 
in 2013 on which positive opinion was issued. Quantitatively and qualitatively 
descriptive analyses towards the new molecules were carried out based on 
the submitted pharmacoeconomic evaluations. Results: 22 new INNs were 
submitted and approved for reimbursement during the studied period (average time 
for approval: 194.55 days). Only 18.18% (n= 4) were orphan drugs. The most com-
monly used types of pharmacoeconomic evaluation were cost-effectiveness analysis 
(n= 10), followed by cost-minimization analysis (n= 4). Only one cost-utility analysis 
was provided. In all other cases only budget impact analyses (BIA) was submitted that 
correspond with the national regulatory requirements. Only one analysis included 
hospitalization costs calculation. The chosen perspective was the payer’s perspective 
for all analyses. The time horizon varies between 10 days and 5 years. 68.18% (n= 15) 
of the pharmacoeconomic evaluations were adjusted to 1 year calculations. 72.73% of 
the INNs were approved for 100% reimbursement rate, 3 INNs – for 75% and two-for 
50% reimbursement rate. 45.45% of the submitted evaluations contained local epide-
miological data. Only one analysis did not include the relevant comparator and only 
two haven’t discussed any additional benefits of the treatment. Pharmacoeconomic 
evaluations of new medicinal products was often inadequately validated by incor-
rect type of pharmacoeconomic analysis chosen, lack of Bulgarian epidemiological 
data, costs and effects were not correctly analyzed which led to prolongation of the 
time need for approval. cOnclusiOns: The need for more detailed guidelines is 
obvious in the light of increasing importance of pharmacoeconomic evaluations for 
reimbursement purposes.
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Objectives: Competitive tendering of active ingredient-specific contracts for 
generic drugs has emerged in Germany due to regulatory changes in 2009. The 
central goal of these changes is to accomplish that small and medium sized firms 
(SME) have better chances to succeed. Another goal is more participation of manu-
facturers, including outright market entry. We study how different designs of the 
competitive tendering affect participation and the outcome of generic drug manu-
facturers. MethOds: We use a newly collected data set on almost all of the around 
4000 public competitive awardings of procurement contracts by purchase groups 
in Germany from the first one in 2008 to the end of 2012. An important source of 
cross-sectional variation is caused by the nine purchasing groups, which differ in 
how they design their awarding procedures. Major differences include the lot size, 
the number of possible contracting firms and whether a drugs of a specific active 
pharmaceutical ingredient is auctioned in one or different lots. We use OLS regres-
sions with fixed effects for unobserved active pharmaceutical ingredient (API) mar-
ket characteristics, as well as count data and discrete choice models. Results: Our 
econometric analysis reveals that there are more bidders in tenders where contracts 
with more than one supplier are possible, when the drugs for one API are auctioned 
in a single lot and when the lot size is smaller. Also small firms are more likely to 
win when multiple winners are possible and the lot size is smaller. cOnclusiOns: 
We find that the design of awarding procedures influences participation in tenders 
and, furthermore, the chance of new suppliers to win the contract. This is relevant 
for both purchasing groups and policy makers as low bids and thus drug expenses 
of the statutory health insurances can only be achieved with a competitive industry 
structure.
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